Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Exploring Psilocybin Treatments in Underserved Indications
July 30, 2021
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Psychedelics — Not Just for Mental Health Anymore.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/i3ouS While it is common knowledge that the use of psychedelic […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day
July 29, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has reported its interim financial results; the results cover the three- and nine-month period ended May 31, 2021. Highlights of the report include Tryp’s collaboration with the Chronic Pain & Fatigue Research […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
July 28, 2021
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Psychedelics — Not Just for Mental Health Anymore,” […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Board Appointments
July 26, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced the appointment of Robin Carhart-Harris, Ph.D. as chairman of Tryp’s Scientific Advisory Board (“SAB”) and Daniel Clauw, M.D. as a new member of the SAB. Dr. Carhart-Harris initially joined […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Preview Milestones for Novel Psychedelic Therapies in Investor Day Event
July 22, 2021
Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program Tryp’s management team […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), University of Michigan to Collaborate in Phase 2a Clinical Trial for Fibromyalgia
July 21, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. […]
InvestorNewsBreaks – Healthtech Solutions Inc. (HLTT) Appoints New Member to Board of Directors
July 21, 2021
Healthtech Solutions (OTC: HLTT), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from preclinical to commercial growth, has named finance and biotech veteran Paul Mann to its board of directors. Mann has worked for two decades in the financial […]
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment
July 20, 2021
Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes […]
Clearmind Issues Shareholder Letter
July 20, 2021
Toronto, July 20, 2021 (GLOBE NEWSWIRE) — via InvestorWire– Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, has issued a letter to shareholders from its Chief Executive Officer Dr. Adi Zuloff-Shani. The […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate
July 16, 2021
San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Upcoming Q3 Investor Day
July 15, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be hosting a third-quarter virtual Investor Day. The company has scheduled this event for July 29, 2021; it will begin at 9 a.m. PDT. Included on the event agenda will […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company
July 8, 2021
Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs It […]
InvestorNewsBreaks – Healthtech Solutions Inc. (HLTT) Expands Board to Add Distinguished Leadership
July 8, 2021
Healthtech Solutions (OTC: HLTT), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the health care system through its subsidiary companies, today announced its appointment of Steve Horowitz to the Board of Directors. Horowitz brings to the Board many years of experience as a business advisor and financial analyst. Horowitz […]
Healthtech Solutions, Inc. Adds Distinguished Leadership To Its Board of Directors
July 8, 2021
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from pre-clinical to commercial growth, announced today that Steve Horowitz was appointed to […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan
July 7, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit
July 2, 2021
Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT It will focus on the psychedelics industry, showcasing the latest research and development within the sector Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program
July 1, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. […]
InvestorNewsBreaks – Healthtech Solutions Inc. (HLTT) Announces New COO, New Board Member
July 1, 2021
Healthtech Solutions (OTC: HLTT), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from preclinical to commercial growth, has named Brad Mathis as its new chief operating officer and Ryan Salomone as a new member of the company’s board of […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management
July 1, 2021
NEW YORK, July 01, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “GW Pharma Sells for Bilions; Psychedelic Company Following Similar Path.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/0N5t5 Many companies are angling to capitalize on the […]
Healthtech Solutions, Inc. Bolsters Management and Board with Two New Appointments
July 1, 2021
NEW YORK, July 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from pre-clinical to commercial growth, announced today that Brad Mathis was named Chief Operating Officer […]
XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track
June 30, 2021
XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program […]
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Ships Initial Order of 0.5 Gram Vape Cartridges
June 30, 2021
Pure Extracts announced initial shipment of 0.5 gram vape cartridges to Alberta Gaming, Liquor & Cannabis CBD vape market has experienced strong growth in recent times, with one market research firm forecasting sector to be worth over $28bn by 2027 Pure Extracts has simultaneously sought to broaden its SKU’s within vape sector, commencing manufacture of […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Charting Its Own Course in Psychedelic Space
June 30, 2021
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “GW Pharma Sells for Bilions; Psychedelic Company Following […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs
June 25, 2021
In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit
June 24, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the […]
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model
June 17, 2021
The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine Cybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO In the first-ever study of its kind, […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast
June 17, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced that chairman and CEO Greg McKee was interviewed on the most recent episode of the Stock2Me Podcast. The podcast features a fascinating array of companies and individuals that are actively revolutionizing business practices within […]
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast featuring Tryp Therapeutics Inc. Chairman and CEO Greg McKee
June 17, 2021
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) — (via InvestorWire) InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference
June 16, 2021
Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference Tryp’s synthetic psychedelic drug candidate will be further developed […]
InvestorNewsBreaks – Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) BC Facility Ready to Meet Increasing Demand
June 15, 2021
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and partnerships. In a corporate update focused on three points of interest in its growing business — cannabis, functional mushrooms and psilocybin — CEO Ben Nikolaevsky noted that the company’s Pemberton, British Columbia facility is […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’
June 15, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Looks to Focus Expertise on Psychedelic Drug Formulation as Manufacturing Programs Advance
June 15, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community. The audio press release discusses […]
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies
June 15, 2021
VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) — via InvestorWire — XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness […]
The MDMA Conference
June 14, 2021
Virtual EventDate: Tues. June 15, 2021Time: 9:00 AM EST The MDMA Conference is a virtual conference exploring the potential of the psychoactive drug MDMA, at the intersection of drug development & safety, clinical care and applications, law & regulation, business & markets, science & research, history & culture. The MDMA Conference will consist of six […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference
June 10, 2021
Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021 As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program Tryp will present alongside other pharmaceutical companies leading research in […]
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files International Patent to Protect Potential Patient Coverage in 153 Countries
June 9, 2021
Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries Cybin filed the PCT application to provide broad international patent protection of key intellectual property Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) Announces Participation at Ladenburg Thalmann Healthcare Conference
June 8, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be presenting at the upcoming Ladenburg Thalmann Healthcare Conference. The all-virtual conference is scheduled for July 13–14, 2021. Tryp chair and CEO Greg McKee, president and chief science officer […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Develops New Treatment Model, Announces Co-Sponsorship of First-Ever Trial to Treat Frontline Clinicians
June 8, 2021
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has developed EMBARK, a transdiagnostic psychotherapy model, and will be co-sponsoring an upcoming trial designed for frontline clinicians experiencing COVID-related distress. Cybin announced that the randomized, placebo-controlled trial will evaluate psychedelic-assisted psychotherapy with psilocybin in the treatment of symptoms of depression, anxiety, […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program
June 8, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto’s psychedelic medicine program and will provide a foundation […]
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Direct-To-Consumer Amazon Store under Pure Mushrooms Brand
June 4, 2021
PULL subsidiary Pure Mushrooms Corp. opens direct-to-consumer e-Commerce store on Amazon platform Store features Reishi, Maitake formulations with plans to add Lion’s Mane in summer 2021 Global functional mushroom market valued at $25.4 billion in 2020, expected CAGR of 8.44% from 2021-2026 Company expands psychedelic vertical through letter of intent with Psyence Group to co-produce […]